Compare Five Below Inc (FIVE) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs BIO-TECHNE Corp — how do they compare? Five Below Inc trades at $209.72 (market cap $11.25B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Five Below Inc and BIO-TECHNE Corp are close in size by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Five Below Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and BIO-TECHNE Corp for 63 Days on average.
| FIVE | TECH | |
|---|---|---|
Market Cap | $11.25B | $11.37B |
Volume | 986,546 | 3,153,511 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $72.61 |
52-Week Low | $138.49 | $43.31 |
Typical Hold Time | 46 Days | 63 Days |
Enterprise Value | $12.10B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $209.56, down 0.17% on the day, with a bearish technical signal despite bullish oscillators. The company shows strong profitability with 40.26% gross margins and 28.25% ROE, though net margins declined to 6.54% in 2025. Recent earnings beats and a raised 2026 outlook highlight growth momentum, supported by store expansion and digital initiatives. Cash flow improved significantly in 2025 with $152M net inflow after two years of negative flows.
The stock offers substantial upside to the $298.44 consensus target, with 60% analyst buy ratings and no sell recommendations. Key risks include premium valuation (P/E 18.32) and execution pressure amid consumer spending concerns. Growth catalysts include the $600M buyback and store revamp strategy, though technical resistance near $212 may limit near-term gains.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
